Annovis has published peer-reviewed Phase 2/3 res
Author: Michael
New funding and partnerships position Endlyz to
Collaboration signals rising confidence in gene
Smart Nanovirus debuts RIGVIR X, a monthly liqui
New trial data point to longer-lasting mobility
Belgian biotech targets SIK3 to shift autoimmune
The U.S.
Alnylam has advanced its investigational RNAi can
Sana Biotechnology announced an abstract highligh
What if aging well isn’t about losing weight,